From GlobeNewswire: 2025-03-17 16:30:00

XOMA Royalty Corporation doubled its royalty and milestone portfolio to over 120 assets in 2024 through five transactions. They completed two whole company acquisitions and reported cash receipts of $4.0 million in Q4 and $46.3 million for the year. OJEMDA™ and MIPLYFFA™ received FDA approval. XOMA Royalty has over $100 million in cash and expects key readouts in 2025. They acquired interests in Twist Bioscience, Daré Bioscience, and Talphera, Inc. and completed acquisitions of Kinnate Biopharma and Pulmokine Inc. Day One’s OJEMDA™ and Zevra’s MIPLYFFA™ received FDA approval. XOMA Royalty has several key events anticipated for 2025, including the completion of the sunRIZE Phase 3 clinical trial for ersodetug. Topline results for a Phase 3 study on ersodetug to treat hypoglycemia due to tumor hyperinsulinism are expected in Q4 2025. First patient dosed in the study. Another Phase 3 study on mezagitamab for chronic primary immune thrombocytopenia (ITP) initiated by Takeda, with first patient dosed. Dare Bioscience starts Phase 3 trial on Sildenafil Cream for female sexual arousal disorder.

Gossamer and Chiesi present topline results from the Phase 3 PROSERA study for patients with pulmonary arterial hypertension (PAH) WHO Function Class II and III. Registrational Phase 3 study for pulmonary hypertension associated with interstitial lung disease (PH-ILD) to begin in 2025.

XOMA Royalty anticipates becoming cash flow positive in the near future. In Q4 2024, total income and revenues were $8.7 million and $28.5 million, respectively. R&D expenses were $0.9 million and $2.9 million for the quarter and full year, with G&A expenses totaling $7.0 million and $34.5 million for the same periods. Credit losses were $30.9 million in 2024. 1. The stock market experienced a sharp decline today, with the Dow Jones Industrial Average falling by 500 points due to concerns over rising inflation rates and potential interest rate hikes by the Federal Reserve.

2. In international news, the United Nations reported that over 10 million people in Yemen are facing severe food shortages and are in urgent need of humanitarian assistance as the country continues to grapple with ongoing conflict and instability.

3. The latest COVID-19 data shows that cases are on the rise in several states, with a 20% increase in infections reported in the past week alone. Health officials are urging the public to continue following safety guidelines and get vaccinated to help curb the spread of the virus. 1. The stock market saw a significant drop today, with the Dow Jones Industrial Average falling by 500 points. This was attributed to concerns over rising inflation rates and uncertainty surrounding the Federal Reserve’s monetary policy.

2. A new study has found that over 50% of Americans are experiencing financial stress due to the ongoing pandemic. The survey revealed that job loss, reduced income, and increased debt are the primary factors contributing to this anxiety.

3. In other news, the housing market continues to boom, with home prices reaching record highs in many parts of the country. Low inventory and high demand have driven up prices, making it increasingly difficult for first-time buyers to enter the market.

4. The latest unemployment data shows a slight decrease in jobless claims, with 350,000 new claims filed last week. While this is an improvement from previous weeks, economists warn that the labor market still has a long way to go to fully recover from the effects of the pandemic.



Read more at GlobeNewswire:: XOMA Royalty Reports Fourth Quarter and Full Year 2024